BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

787 related articles for article (PubMed ID: 32319999)

  • 1. Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial.
    Fiuzat M; Ezekowitz J; Alemayehu W; Westerhout CM; Sbolli M; Cani D; Whellan DJ; Ahmad T; Adams K; Piña IL; Patel CB; Anstrom KJ; Cooper LS; Mark D; Leifer ES; Felker GM; Januzzi JL; O'Connor CM
    JAMA Cardiol; 2020 Jul; 5(7):757-764. PubMed ID: 32319999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction.
    Daubert MA; Yow E; Barnhart HX; Piña IL; Ahmad T; Leifer E; Cooper L; Desvigne-Nickens P; Fiuzat M; Adams K; Ezekowitz J; Whellan DJ; Januzzi JL; O'Connor CM; Felker GM
    J Am Heart Assoc; 2021 May; 10(10):e019712. PubMed ID: 33955231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
    Felker GM; Anstrom KJ; Adams KF; Ezekowitz JA; Fiuzat M; Houston-Miller N; Januzzi JL; Mark DB; Piña IL; Passmore G; Whellan DJ; Yang H; Cooper LS; Leifer ES; Desvigne-Nickens P; O'Connor CM
    JAMA; 2017 Aug; 318(8):713-720. PubMed ID: 28829876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
    Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
    Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study.
    Kimmoun A; Cotter G; Davison B; Takagi K; Addad F; Celutkiene J; Chioncel O; Solal AC; Diaz R; Damasceno A; Duengen HD; Filippatos G; Goncalvesova E; Merai I; Metra M; Ponikowski P; Privalov D; Sliwa K; Sani MU; Voors AA; Shogenov Z; Mebazaa A
    Eur J Heart Fail; 2019 Nov; 21(11):1459-1467. PubMed ID: 31423712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
    Felker GM; Ahmad T; Anstrom KJ; Adams KF; Cooper LS; Ezekowitz JA; Fiuzat M; Houston-Miller N; Januzzi JL; Leifer ES; Mark DB; Desvigne-Nickens P; Paynter G; Piña IL; Whellan DJ; O'Connor CM
    JACC Heart Fail; 2014 Oct; 2(5):457-65. PubMed ID: 25194287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guideline-Directed Medical Therapy Tolerability in Patients With Heart Failure and Mitral Regurgitation: The COAPT Trial.
    Cox ZL; Zalawadiya SK; Simonato M; Redfors B; Zhou Z; Kotinkaduwa L; Zile MR; Udelson JE; Lim DS; Grayburn PA; Mack MJ; Abraham WT; Stone GW; Lindenfeld J
    JACC Heart Fail; 2023 Jul; 11(7):791-805. PubMed ID: 37115135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction.
    Januzzi JL; Ahmad T; Mulder H; Coles A; Anstrom KJ; Adams KF; Ezekowitz JA; Fiuzat M; Houston-Miller N; Mark DB; Piña IL; Passmore G; Whellan DJ; Cooper LS; Leifer ES; Desvigne-Nickens P; Felker GM; O'Connor CM
    J Am Coll Cardiol; 2019 Sep; 74(9):1205-1217. PubMed ID: 31466618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Background pharmacological therapy in the ANTHEM-HF: comparison to contemporary trials of novel heart failure therapies.
    Premchand RK; Sharma K; Mittal S; Monteiro R; Libbus I; Ardell JL; Gregory DD; KenKnight BH; Amurthur B; DiCarlo LA; Anand IS
    ESC Heart Fail; 2019 Oct; 6(5):1052-1056. PubMed ID: 31339232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient Perceptions and Familiarity With Medical Therapy for Heart Failure.
    Samsky MD; Lin L; Greene SJ; Lippmann SJ; Peterson PN; Heidenreich PA; Laskey WK; Yancy CW; Greiner MA; Hardy NC; Kavati A; Park S; Mentz RJ; Fonarow GC; O'Brien EC
    JAMA Cardiol; 2020 Mar; 5(3):292-299. PubMed ID: 31734700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry.
    Tomasoni D; Pagnesi M; Colombo G; Chiarito M; Stolfo D; Baldetti L; Lombardi CM; Adamo M; Maggi G; Inciardi RM; Loiacono F; Maccallini M; Villaschi A; Gasparini G; Montella M; Contessi S; Cocianni D; Perotto M; Barone G; Merlo M; Cappelletti AM; Rosano G; Sinagra G; Pini D; Savarese G; Metra M
    Eur J Heart Fail; 2024 Feb; 26(2):327-337. PubMed ID: 37933210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure.
    Fuery MA; Chouairi F; Januzzi JL; Moe GW; Caraballo C; McCullough M; Miller PE; Reinhardt SW; Clark K; Oseran A; Milner A; Pacor J; Kahn PA; Singh A; Ravindra N; Guha A; Vadlamani L; Kulkarni NS; Fiuzat M; Felker GM; O'Connor CM; Ahmad T; Ezekowitz J; Desai NR
    JACC Heart Fail; 2021 Jul; 9(7):497-505. PubMed ID: 33992564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart Failure.
    Wirtz HS; Sheer R; Honarpour N; Casebeer AW; Simmons JD; Kurtz CE; Pasquale MK; Globe G
    J Am Heart Assoc; 2020 Aug; 9(16):e015042. PubMed ID: 32805181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry.
    Greene SJ; Butler J; Hellkamp AS; Spertus JA; Vaduganathan M; Devore AD; Albert NM; Patterson JH; Thomas L; Williams FB; Hernandez AF; Fonarow GC
    J Card Fail; 2022 Mar; 28(3):370-384. PubMed ID: 34793971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized Clinical Trial.
    Cotter G; Deniau B; Davison B; Edwards C; Adamo M; Arrigo M; Barros M; Biegus J; Celutkiene J; Cerlinskaite-Bajore K; Chioncel O; Cohen-Solal A; Damasceno A; Diaz R; Filippatos G; Gayat E; Kimmoun A; Lam CSP; Metra M; Novosadova M; Pang PS; Pagnesi M; Ponikowski P; Saidu H; Sliwa K; Takagi K; Ter Maaten JM; Tomasoni D; Voors A; Mebazaa A
    JAMA Cardiol; 2024 Feb; 9(2):114-124. PubMed ID: 38150260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guideline-Directed Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction in the Community.
    Dunlay SM; Killian JM; Roger VL; Schulte PJ; Blecker SB; Savitz ST; Redfield MM
    J Card Fail; 2022 Oct; 28(10):1500-1508. PubMed ID: 35902033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
    DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
    JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction.
    Kocabaş U; Ergin I; Kıvrak T; Yılmaz Öztekin GM; Tanık VO; Özdemir İ; Avcı Demir F; Doğduş M; Şen T; Altınsoy M; Üstündağ S; Urgun ÖD; Sinan ÜY; Uygur B; Yeni M; Özçalık E
    ESC Heart Fail; 2023 Dec; 10(6):3677-3689. PubMed ID: 37804042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Titration of medications and outcomes in multi-ethnic heart failure cohorts (with reduced ejection fraction) from Singapore and New Zealand.
    Teng TK; Tay WT; Ouwerkerk W; Tromp J; Richards AM; Gamble G; Greene SJ; Yiu KH; Poppe K; Ling LH; Lund M; Sim D; Devlin G; Loh SY; Troughton R; Ren QW; Jaufeerally F; Lee SGS; Tan RS; Soon DKN; Leong G; Ong HY; Yeo DPS; Lam CSP; Doughty RN
    ESC Heart Fail; 2023 Apr; 10(2):1280-1293. PubMed ID: 36722315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.